Advanced searches left 3/3

Carcinoma pembrolizumab - Crossref

Summarized by Plex Scholar
Last Updated: 03 September 2022

* If you want to update the article please login/register

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Abstract A phase II review of patients with pre-treated persistent/recurrent/metastatic cervical or endometrial cancer is published. Patients were given an immunomodulatory five-drug cocktail containing low-dose cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin, beginning 2 weeks before radioimmunotherapy. Pepolizumab was administered three weeks from day 15 to day 19; one of the tumor lesions was irradiated on days 15, 17, and 19. At week 26, the primary endpoint was the objective response rate per immune-related response criteria. The irORR was 11. 1% in cervical cancer and 12. 0% in endometrial cancer. Median interval-censored progression-free survival was 4. 1 weeks in cervical cancer and 3. 6 weeks in endometrial cancer; median overall survival was 39. 6 weeks and 37. 4 weeks, respectively. In ten cervical cancer patients and nine endometrial cancer patients, there were three incidences of treatment-related adverse events. Comparing to nonresponders, responders had a significantly higher number of peripheral T cells.

Source link: https://doi.org/10.1007/s00262-022-03253-x


A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice

Abstract Summary of PD-L1 genes is a part of clinical therapy for elderly patients with lung cancer who are unable to tolerate chemotherapy, do not have cancer driver genes, and have poor expressions of PD-L1. We present a 71-year-old male patient with advanced lung adenocarcinoma lacking primary driving genes and a low rate of PD-L1 on tumor cells. The tumor tissue demonstrated a low degree of microsatellite instability, low tumor mutational prevalence, and no DNA mismatch repair deficiency on whole-exome sequencing. Liquid biopsy technology and WES may be useful in overcoming tissue biopsy's limitations.

Source link: https://doi.org/10.1515/med-2021-0404


Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report

Abstract This is a rare and aggressive cancer with a poor prognosis, and it is often associated with large-cell neuroendocrine carcinomas. We've included a 59-year-old male patient with advanced LCNEC with a non-neuroendocrine immunophenotype who was treated with endostar plus pembrolizumab in a first-line therapy in conjunction with a platinum-based dual chemotherapy regimen as a first-line therapy. This case report discussed the possibility of immunotherapy, anti-angiogenesis products, and chemotherapy as a first-line therapy in advanced LCNEC.

Source link: https://doi.org/10.1515/biol-2022-0062


Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China

Although peterolizumab is indicated as a first-line treatment for acute/unresectable/metastatic head and neck squamous carcinoma in children, different populations need to be investigated. At the Affiliated Hospital of Qingdao University from February 2021 to May 2022, we reviewed 15 patients with R/U/M oral squamous cell carcinoma treated with pembrolizumab monotherapy. All 15 patients were aware of programmed death-ligand 1 expression and received multiple cycles of pegolizumab monotherapy as first-line therapy. In two to five cycles, the patient's objective response status was found in our research. The mean Karnofsky Performance Status score after therapy was significantly higher than that before therapy for patients who responded well to immunotherapy. In our single-center study, pembrolizumab is shown to be highly effective to the most active patients with R/U/M OSCC, and it may help to improve OSCC management.

Source link: https://doi.org/10.1155/2022/7283946


Association of Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma With Adverse Events After Surgery in Treatment-Naive Patients

The U. S. Food and Drug Administration has recently approved recurrent or metastatic head and neck squamous cell carcinoma, Importance Pepeb, a monoclonal antibody targeted programmed cell death, for recurrent or metastatic head and neck squamous cell carcinoma. The potential neoadjuvant role of programmed cell death 1 inhibitors in primary surgical care of HNSCC and its effects on surgical outcomes are uncertain. As part of a window-of-opportunity multi-institutional clinical trial evaluating neoadjuvant pembrolizumab for locally advanced HNSCC, we will determine the incidence of postoperative adverse events in treatment-nay patients with advanced oral cavity cancer receiving neoadjuvant pembrolizumab. Conclusions and Relevance This cohort looked at surgical risks in patients with local regionally advanced OCSCC treated with neoadjuvant pegolizumab and discovered that major adverse events were similar to those in patients undergoing standard-of-care therapy.

Source link: https://doi.org/10.1001/jamaoto.2022.2291


EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma

Patients with metastatic urothelial carcinoma have poor prognosis as a result of poor first-line chemotherapy failures. Low response rates have been recorded at the time in which an important unmet need exists. MATERIALS AND METHODS Patients with metastatic urothelial carcinoma that recurred or progressed after platinum-based chemotherapy received soluble EphB4-human serum albumin in combination with petolizumab in this phase II trial. Results were correlated with the expression of sEphB4-HSA's EphrinB2 target EphrinB2. RESULTS Seventy patients were enrolled. The median OS was 14. 6 months in the intent-to-treat study. About 24% versus a complete response rate of 24% among the forty-six patients who expressed EphrinB2, the median OS was 21. 5 months, with five out of six patients reporting it. CONCLUSION With improved OS and ORR, the combination of sEphB4-HSA and peeblozumab appears to be synergistic, according to historical results for programmed death ligand 1 monotherapy.

Source link: https://doi.org/10.1200/jco.21.02923


Neoadjuvant pembrolizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim results.

Background: e16011 is a summary of esophageal squamous cell carcinoma, the most common form of esophageal cancer in China. In patients with locally advanced ESCC, we conducted a prospective clinical trial of pre-operative penetolizumab with chemotherapy. Patients with clinical stage IIB-IVA ESCC eligible for resectable surgery were prospectively enrolled in reconstructible surgery. For four cycles before surgery, patients were prescribed neoadjuvant pegymab and chemotherapy every three weeks for four weeks. Following neoadjuvant therapy, twenty-four patients have completed four cycles of neoadjuvant therapy, of whom 22 patients were radiologically evaluable after neoadjuvant therapy. Among 22 patients with resectable tumors, 14 patients underwent McKeown MIE, and 5 patients are also waiting for the surgery. All 14 patients who underwent esophagectomy within 29-74 days after neoadjuvant therapy had radical resection. In locally advanced ESCC, Neoadjuvant petalozumab plus chemotherapy has had promising initial efficacy and safety results.

Source link: https://doi.org/10.1200/jco.2022.40.16_suppl.e16011


Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma

To our knowledge, this is the first reported case of PD-1 inhibitor-associated Type 1 diabetes mellitus in a patient with cholangiocarcinoma, although others with a cholangiocarcinoma experience find that PD-1 inhibition can cause a variety of autoimmune diseases that nec necessitate clinical monitoring and periodic testing.

Source link: https://doi.org/10.2217/imt-2017-0042


Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report

Although pembrolizumab's effectiveness and safety in patients with refractory/recurrent thymic carcinoma that progressed after chemotherapy, the safety and effectiveness of combination of pembrolizumab and chemotherapy as front-line treatment in metastatic thymic carcinoma have yet to be investigated. We present the first two cases of metastatic thymic cell carcinoma receiving both penet and chemotherapy as first-line therapy. Patient 1 had high PD-L1 expression in patient 1 and poor PD-L1 expression in patient 2. Immunohistochemistry evaluation of the tumor revealed high PD-L1 expression in patient 1 and low PD-L1 expression in patient 2.

Source link: https://doi.org/10.3389/fimmu.2022.941092


Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: A retrospective, single-center, three-arm study

Peripolizumab, as well as paclitaxel and platinum, was used in the treatment of locally diagnosed and possibly resectable esophageal squamous cell carcinoma. Methods In this retrospective, single-arm review, patients with locally advanced and potentially resectable ESCC were given pesolizumab in combination with paclitaxel and neplatin as induction therapy once every three weeks. Patients who underwent radical radiotherapy were divided into group A, patients who underwent radical radiotherapy were divided into group B, and patients who did not attend any radical radiotherapy were divided into group B, and patients who did not undergo any radical radiotherapy were divided into group B, and patients who did not complete radical radiotherapy were divided into group B. Pemobinizumab maintenance therapy was administered in both 3 groups. After an immune response assessment in the first stage, 34 patients developed immune partial response, and 5 patients developed immune stable disease. After the tumors had shrunk drastically, nine patients in group B chose radiotherapy as the new therapeutic approach. None of the eight patients in group C received no radical therapy. Pembrolizumab therapy was discontinued for all patients, and the median period of pembrolizumab therapy was 8 cycles. Peparolizumab in combination with paclitaxel and platinum as induction therapy for locally advanced and potentially resectable ESCC has a high ORR, increased surgical conversion, MPR, pCR, and R0 resection rates, as well as tolerable AEs in the operation group, as induction therapy for locally advanced and potentially resectable ESCC. Pemolizumab could be helpful in sequential radiotherapy or maintenance therapy for patients who are unable to undergo surgical care.

Source link: https://doi.org/10.21203/rs.3.rs-1902307/v1

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions